Daniella Mehalik
Direttore Finanziario/CFO presso PSYCHEMEDICS CORPORATION
Posizioni attive di Daniella Mehalik
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PSYCHEMEDICS CORPORATION | Direttore Finanziario/CFO | 27/11/2023 | - |
| Contatto Relazioni con gli Investitori | - | - | |
| Treasurer | 27/11/2023 | - |
Storia della carriera di Daniella Mehalik
Precedenti posizioni note di Daniella Mehalik
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/01/2021 | 01/01/2023 |
| DxTx Medical, Inc. | Comptroller/Controller/Auditor | 01/01/2019 | 01/01/2021 |
Formazione di Daniella Mehalik
| Carlow University Of | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
| Investor Relations Contact | 1 |
Settori
| Health Services | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PSYCHEMEDICS CORPORATION | Health Services |
| Aziende private | 2 |
|---|---|
NeuBase Therapeutics, Inc.
 NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on March 29, 2002 and is headquartered in Pittsburgh, PA. | Health Technology |
| DxTx Medical, Inc. |
- Borsa valori
- Insiders
- Daniella Mehalik
- Esperienza
